More favorable response to cardiac resynchronization therapy in women than in men

Circulation: Arrhythmia and Electrophysiology

Volumn 7, Issue 5, 2014, Pages 807-815

  Cheng, Yun Jiu ^a   Zhang, Jing ^a,b   Li, Wei Jie ^a   Lin, Xiao Xiong ^a   Zeng, Wu Tao ^a   Tang, Kai ^a   Tang, An Li ^a   He, Jian Gui ^a   Xu, Qing ^a   Mei, Mei Yi ^a   Zheng, Dong Dan ^a   Dong, Yu Gang ^a   Ma, Hong ^a   Wu, Su Hua ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b Guangxi Liuzhou Municipal Liutie Central Hospital   (China)

Author keywords

cardiac resynchronization therapy; Meta analysis; Mortality; Sex characteristics

Indexed keywords

CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR RISK; CAUSE OF DEATH; ECHOCARDIOGRAPHY; EXERCISE TOLERANCE; FUNCTIONAL STATUS; HEART DEATH; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE ARRHYTHMIA; HOSPITALIZATION; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QRS COMPLEX; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEX DIFFERENCE; SUDDEN CARDIAC DEATH; SYSTEMATIC REVIEW; TREATMENT RESPONSE; ADVERSE EFFECTS; CONVALESCENCE; DEATH, SUDDEN, CARDIAC; FEMALE; HEART VENTRICLE REMODELING; KAPLAN MEIER METHOD; MALE; MORTALITY; PATHOPHYSIOLOGY; RISK; RISK FACTOR; TREATMENT OUTCOME;

CARDIAC RESYNCHRONIZATION THERAPY; DEATH, SUDDEN, CARDIAC; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; ODDS RATIO; RECOVERY OF FUNCTION; RISK FACTORS; SEX FACTORS; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 84925229534     PISSN: 19413149     EISSN: 19413084     Source Type: Journal    
DOI: 10.1161/CIRCEP.113.001786     Document Type: Review

References (69)

1. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:1810-1852.
2. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM; Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140-2150.
3. Linde C, Abraham WT, Gold MR, St John Sutton M, Ghio S, Daubert C; REVERSE (REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction) Study Group. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol. 2008;52:1834-1843.
4. Arshad A, Moss AJ, Foster E, Padeletti L, Barsheshet A, Goldenberg I, Greenberg H, Hall WJ, McNitt S, Zareba W, Solomon S, Steinberg JS; MADIT-CRT Executive Committee. Cardiac resynchronization therapy is more effective in women than in men: the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) trial. J Am Coll Cardiol. 2011;57:813-820.
5. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-1558.
6. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634.
7. Xu YZ, Friedman PA, Webster T, Brooke K, Hodge DO, Wiste HJ, Hua W, Zhang S, Hayes DL, Cha YM. Cardiac resynchronization therapy: do women benefit more than men? J Cardiovasc Electrophysiol. 2012;23:172-178.
8. Lilli A, Ricciardi G, Porciani MC, Perini AP, Pieragnoli P, Musilli N, Colella A, Del Pace S, Michelucci A, Turreni F, Sassara M, Achilli A, Barold SS, Padeletti L. Cardiac resynchronization therapy: gender related differences in left ventricular reverse remodeling. Pacing Clin Electrophysiol. 2007;30:1349-1355.
9. Mooyaart EA, Marsan NA, van Bommel RJ, Thijssen J, Borleffs CJ, Delgado V, van der Wall EE, Schalij MJ, Bax JJ. Comparison of longterm survival of men versus women with heart failure treated with cardiac resynchronization therapy. Am J Cardiol. 2011;108:63-68.
10. Zardkoohi O, Nandigam V, Murray L, Heist EK, Mela T, Orencole M, Ruskin JN, Singh JP. The impact of age and gender on cardiac resynchronization therapy outcome. Pacing Clin Electrophysiol. 2007;30:1344-1348.
11. Woo GW, Petersen-Stejskal S, Johnson JW, Conti JB, Aranda JA Jr, Curtis AB. Ventricular reverse remodeling and 6-month outcomes in patients receiving cardiac resynchronization therapy: analysis of the MIRACLE study. J Interv Card Electrophysiol. 2005;12:107-113.
12. Zabarovskaja S, Gadler F, Braunschweig F, Ståhlberg M, Hörnsten J, Linde C, Lund LH. Women have better long-term prognosis than men after cardiac resynchronization therapy. Europace. 2012;14:1148-1155.
13. Schuchert A, Muto C, Maounis T, Frank R, Ella RO, Polauck A, Padeletti L; MASCOT Study Group. Gender-related safety and efficacy of cardiac resynchronization therapy. Clin Cardiol. 2013;36:683-690.
14. Amit G, Suleiman M, Konstantino Y, Luria D, Kazatsker M, Chetboun I, Haim M, Gavrielov-Yusim N, Goldenberg I, Glikson M; Israeli Working Group on Pacing and Electrophysiology. Sex differences in implantable cardioverter-defibrillator implantation indications and outcomes: lessons from the Nationwide Israeli-ICD Registry. Europace. 2014;16:1175-1180.
15. Davis DR, Krahn AD, Tang AS, Lemery R, Green MS, Gollob M, Yee R, Skanes AC, Klein GJ, Birnie DH. Long-term outcome of cardiac resynchronization therapy in patients with severe congestive heart failure. Can J Cardiol. 2005;21:413-417.
16. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539-1549.
17. Yu CM, Bleeker GB, Fung JW, Schalij MJ, Zhang Q, van der Wall EE, Chan YS, Kong SL, Bax JJ. Left ventricular reverse remodeling but not clinical improvement predicts long-term survival after cardiac resynchronization therapy. Circulation. 2005;112:1580-1586.
18. Auricchio A, Metra M, Gasparini M, Lamp B, Klersy C, Curnis A, Fantoni C, Gronda E, Vogt J; Multicenter Longitudinal Observational Study (MILOS) Group. Long-term survival of patients with heart failure and ventricular conduction delay treated with cardiac resynchronization therapy. Am J Cardiol. 2007;99:232-238.
19. Inoue N, Takahashi N, Ishikawa T, Sumita S, Kobayashi T, Matsushita K, Matsumoto K, Taima M, Shimura M, Uchino K, Kimura K, Inoue T, Umemura S. Reverse perfusion-metabolism mismatch predicts good prognosis in patients undergoing cardiac resynchronization therapy: a pilot study. Circ J. 2007;71:126-131.
20. Bai R, Di Biase L, Elayi C, Ching CK, Barrett C, Philipps K, Lim P, Patel D, Callahan T, Martin DO, Arruda M, Schweikert RA, Saliba WI, Wilkoff B, Natale A. Mortality of heart failure patients after cardiac resynchronization therapy: identification of predictors. J Cardiovasc Electrophysiol. 2008;19:1259-1265.
21. Di Biase L, Auricchio A, Sorgente A, Civello K, Klersy C, Faletra F, Riedlbauchova L, Patel D, Arruda M, Schweikert RA, Martin DO, Saliba WI, Moccetti T, Wilkoff BL, Natale A. The magnitude of reverse remodelling irrespective of aetiology predicts outcome of heart failure patients treated with cardiac resynchronization therapy. Eur Heart J. 2008;29:2497-2505.
22. El-Saed A, Voigt A, Shalaby A. Usefulness of brain natriuretic peptide level at implant in predicting mortality in patients with advanced but stable heart failure receiving cardiac resynchronization therapy. Clin Cardiol. 2009;32:E33-E38.
23. Fantoni C, Regoli F, Ghanem A, Raffa S, Klersy C, Sorgente A, Faletra F, Baravelli M, Inglese L, Salerno-Uriarte JA, Klein HU, Moccetti T, Auricchio A. Long-term outcome in diabetic heart failure patients treated with cardiac resynchronization therapy. Eur J Heart Fail. 2008;10:298-307.
24. Ferreira AM, Adragão P, Cavaco DM, Candeias R, Morgado FB, Santos KR, Santos E, Silva JA. Benefit of cardiac resynchronization therapy in atrial fibrillation patients vs. patients in sinus rhythm: the role of atrioventricular junction ablation. Europace. 2008;10:809-815.
25. Iler MA, Hu T, Ayyagari S, Callahan TD IV, Civello KC, Thal SG, Wilkoff BL, Chung MK. Prognostic value of electrocardiographic measurements before and after cardiac resynchronization device implantation in patients with heart failure due to ischemic or nonischemic cardiomyopathy. Am J Cardiol. 2008;101:359-363.
26. Landolina M, Gasparini M, Lunati M, Santini M, Rordorf R, Vincenti A, Diotallevi P, Montenero AS, Bonanno C, De Santo T, Valsecchi S, Padeletti L; InSync/InSync ICD Italian Registry Investigators. Heart rate variability monitored by the implanted device predicts response to CRT and long-term clinical outcome in patients with advanced heart failure. Eur J Heart Fail. 2008;10:1073-1079.
27. Kronborg MB, Mortensen PT, Kirkfeldt RE, Nielsen JC. Very long term follow-up of cardiac resynchronization therapy: clinical outcome and predictors of mortality. Eur J Heart Fail. 2008;10:796-801.
28. Shalaby A, Voigt A, El-Saed A, Saba S. Usefulness of pulmonary artery pressure by echocardiography to predict outcome in patients receiving cardiac resynchronization therapy heart failure. Am J Cardiol. 2008;101:238-241.
29. Stabile G, Solimene F, Bertaglia E, La Rocca V, Accogli M, Scaccia A, Marrazzo N, Zoppo F, Turco P, Iuliano A, Shopova G, Ciardiello C, De Simone A. Long-term outcomes of CRT-PM versus CRT-D recipients. Pacing Clin Electrophysiol. 2009;32(suppl 1):S141-S145.
30. Zhang Q, Yip GW, Chan YS, Fung JW, Chan W, Lam YY, Yu CM. Incremental prognostic value of combining left ventricular lead position and systolic dyssynchrony in predicting long-term survival after cardiac resynchronization therapy. Clin Sci (Lond). 2009;117:397-404.
31. Cabrera-Bueno F, Fernández-Pastor J, Molina-Mora MJ, Alzueta J, Peña- Hernández JL, Barrera A, de Teresa-Galván E. Combined resynchronization therapy and automatic defibrillator in advanced non-ischaemic heart failure: the importance of QRS width. Europace. 2010;12:92-95.
32. Delgado V, van Bommel RJ, Bertini M, Borleffs CJ, Marsan NA, Arnold CT, Nucifora G, van de Veire NR, Ypenburg C, Boersma E, Holman ER, Schalij MJ, Bax JJ. Relative merits of left ventricular dyssynchrony, left ventricular lead position, and myocardial scar to predict long-term survival of ischemic heart failure patients undergoing cardiac resynchronization therapy. Circulation. 2011;123:70-78.
33. Lin G, Gersh BJ, Greene EL, Redfield MM, Hayes DL, Brady PA. Renal function and mortality following cardiac resynchronization therapy. Eur Heart J. 2011;32:184-190.
34. Pfau G, Schilling T, Kozian A, Lux A, Götte A, Huth C, Hachenberg T. Outcome after implantation of cardiac resynchronization/defibrillation systems in patients with congestive heart failure and left bundle-branch block. J Cardiothorac Vasc Anesth. 2010;24:30-36.
35. Abreu CD, Xavier RM, Nascimento JS, Ribeiro AL. Long-term outcome after Cardiac Resynchronization Therapy: a nationwide database. Int J Cardiol. 2012;155:492-493.
36. Foley PW, Chalil S, Khadjooi K, Irwin N, Smith RE, Leyva F. Left ventricular reverse remodelling, long-term clinical outcome, and mode of death after cardiac resynchronization therapy. Eur J Heart Fail. 2011;13:43-51.
37. Miller AL, Kramer DB, Lewis EF, Koplan B, Epstein LM, Tedrow U. Eventfree survival following CRT with surgically implanted LV leads versus standard transvenous approach. Pacing Clin Electrophysiol. 2011;34:490-500.
38. Prochnau D, Kuehnert H, Heinke M, Figulla HR, Surber R. Left ventricular lead position and nonspecific conduction delay are predictors of mortality in patients during cardiac resynchronization therapy. Can J Cardiol. 2011;27:363-368.
39. Rickard J, Brennan DM, Martin DO, Hsich E, Tang WH, Lindsay BD, Starling RC, Wilkoff BL, Grimm RA. The impact of left ventricular size on response to cardiac resynchronization therapy. Am Heart J. 2011;162:646-653.
40. Shen X, Nair CK, Holmberg MJ, Mooss AN, Koruth J, Wang F, Maciejewski S, Esterbrooks DJ. Impact of left atrial volume in prediction of outcome after cardiac resynchronization therapy. Int J Cardiol. 2011;152:13-17.
41. Smit MD, Maass AH, Hillege HL, Wiesfeld AC, Van Veldhuisen DJ, Van Gelder IC. Prognostic importance of natriuretic peptides and atrial fibrillation in patients receiving cardiac resynchronization therapy. Eur J Heart Fail. 2011;13:543-550.
42. Van Bommel RJ, Mollema SA, Borleffs CJ, Bertini M, Ypenburg C, Marsan NA, Delgado V, Van Der Wall EE, Schalij MJ, Bax JJ. Impaired renal function is associated with echocardiographic nonresponse and poor prognosis after cardiac resynchronization therapy. J Am Coll Cardiol. 2011;57:549-555.
43. Eitel C, Wilton SB, Switzer N, Cowan K, Exner DV. Baseline delayed left ventricular activation predicts long-term clinical outcome in cardiac resynchronization therapy recipients. Europace. 2012;14:358-364.
44. Bogale N, Priori S, Cleland JG, Brugada J, Linde C, Auricchio A, van Veldhuisen DJ, Limbourg T, Gitt A, Gras D, Stellbrink C, Gasparini M, Metra M, Derumeaux G, Gadler F, Buga L, Dickstein K; Scientific Committee, National Coordinators, and Investigators. The European CRT Survey: 1 year (9-15 months) follow-up results. Eur J Heart Fail. 2012;14:61-73.
45. Kreuz J, Horlbeck F, Linhart M, Mellert F, Fimmers R, Schrickel J, Nickenig G, Schwab JO. Independent predictors of mortality in patients with advanced heart failure treated by cardiac resynchronization therapy. Europace. 2012;14:1596-1601.
46. Morani G, Gasparini M, Zanon F, Casali E, Spotti A, Reggiani A, Bertaglia E, Solimene F, Molon G, Accogli M, Tommasi C, Paoletti Perini A, Ciardiello C, Padeletti L. Cardiac resynchronization therapy-defibrillator improves long-term survival compared with cardiac resynchronization therapy-pacemaker in patients with a class IA indication for cardiac resynchronization therapy: data from the Contak Italian Registry. Europace. 2013;15:1273-1279.
47. Shukla A, Curtis AB, Mehra MR, Albert NM, Gheorghiade M, Heywood JT, Liu Y, O'Connor CM, Reynolds D, Walsh MN, Yancy CW, Fonarow GC. Factors associated with improvement in utilization of cardiac resynchronization therapy in eligible heart failure patients: findings from IMPROVE HF. Pacing Clin Electrophysiol. 2013;36:433-443.
48. Risum N, Williams ES, Khouri MG, Jackson KP, Olsen NT, Jons C, Storm KS, Velazquez EJ, Kisslo J, Bruun NE, Sogaard P. Mechanical dyssynchrony evaluated by tissue Doppler cross-correlation analysis is associated with long-term survival in patients after cardiac resynchronization therapy. Eur Heart J. 2013;34:48-56.
49. Frigerio M, Lunati M, Pasqualucci D, Vargiu S, Foti G, Pedretti S, Vittori C, Cattafi G, Magenta G, Campo C, Bisetti S, Mercuro G. Left ventricular ejection fraction overcrossing 35% after one year of cardiac resynchronization therapy predicts long term survival and freedom from sudden cardiac death: single center observational experience. Int J Cardiol. 2014;172:64-71.
50. Gasparini M, Leclercq C, Yu CM, Auricchio A, Steinberg JS, Lamp B, Klersy C, Leyva F. Absolute survival after cardiac resynchronization therapy according to baseline QRS duration: a multinational 10-year experience: data from the Multicenter International CRT Study. Am Heart J. 2014;167:203-209.e1.
51. Reitan C, Bakos Z, Platonov PG, Hoijer CJ, Brandt J, Wang L, Borgquist R. Patient-assessed short-term positive response to cardiac resynchronization therapy is an independent predictor of long-term mortality [published online ahead of print March 28, 2014]. Europace. doi:10.1093/europace/euu058.
52. Schuchert A, Muto C, Maounis T, Frank R, Ella RO, Polauck A, Padeletti L; MASCOT Study Group. Gender-related safety and efficacy of cardiac resynchronization therapy. Clin Cardiol. 2013;36:683-690.
53. Ghali JK, Piña IL, Gottlieb SS, Deedwania PC, Wikstrand JC; MERIT-HF Study Group. Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). Circulation. 2002;105:1585-1591.
54. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med. 2002;347:1403-1411.
55. Ghanbari H, Dalloul G, Hasan R, Daccarett M, Saba S, David S, Machado C. Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials. Arch Intern Med. 2009;169:1500-1506.
56. Santangeli P, Pelargonio G, Dello Russo A, Casella M, Bisceglia C, Bartoletti S, Santarelli P, Di Biase L, Natale A. Gender differences in clinical outcome and primary prevention defibrillator benefit in patients with severe left ventricular dysfunction: a systematic review and meta-analysis. Heart Rhythm. 2010;7:876-882.
57. Rho RW, Patton KK, Poole JE, Cleland JG, Shadman R, Anand I, Maggioni AP, Carson PE, Swedberg K, Levy WC. Important differences in mode of death between men and women with heart failure who would qualify for a primary prevention implantable cardioverter-defibrillator. Circulation. 2012;126:2402-2407.
58. Taneja T, Mahnert BW, Passman R, Goldberger J, Kadish A. Effects of sex and age on electrocardiographic and cardiac electrophysiological properties in adults. Pacing Clin Electrophysiol. 2001;24:16-21.
59. Casale PN, Devereux RB, Alonso DR, Campo E, Kligfield P. Improved sex-specific criteria of left ventricular hypertrophy for clinical and computer interpretation of electrocardiograms: validation with autopsy findings. Circulation. 1987;75:565-572.
60. Cheng S, Xanthakis V, Sullivan LM, Lieb W, Massaro J, Aragam J, Benjamin EJ, Vasan RS. Correlates of echocardiographic indices of cardiac remodeling over the adult life course: longitudinal observations from the Framingham Heart Study. Circulation. 2010;122:570-578.
61. Cheng S, Fernandes VR, Bluemke DA, McClelland RL, Kronmal RA, Lima JA. Age-related left ventricular remodeling and associated risk for cardiovascular outcomes: the Multi-Ethnic Study of Atherosclerosis. Circ Cardiovasc Imaging. 2009;2:191-198.
62. Fantoni C, Raffa S, Regoli F, Giraldi F, La Rovere MT, Prentice J, Pastori F, Fratini S, Salerno-Uriarte JA, Klein HU, Auricchio A. Cardiac resynchronization therapy improves heart rate profile and heart rate variability of patients with moderate to severe heart failure. J Am Coll Cardiol. 2005;46:1875-1882.
63. Martínez-Sellés M, Doughty RN, Poppe K, Whalley GA, Earle N, Tribouilloy C, McMurray JJ, Swedberg K, Køber L, Berry C, Squire I; Meta-Analysis Global Group In Chronic Heart Failure (MAGGIC). Gender and survival in patients with heart failure: interactions with diabetes and aetiology. Results from the MAGGIC individual patient metaanalysis. Eur J Heart Fail. 2012;14:473-479.
64. Dickstein K, Bogale N, Priori S, Auricchio A, Cleland JG, Gitt A, Limbourg T, Linde C, van Veldhuisen DJ, Brugada J; Scientific Committee; National Coordinators. The European cardiac resynchronization therapy survey. Eur Heart J. 2009;30:2450-2460.
65. Mezu U, Bott-Silverman C, Hsich E. Heart failure in women is different than in men; should treatment be different? Cleve Clin J Med. 2007;74:423-424, 426, 429.
66. Hsich EM, Piña IL. Heart failure in women: a need for prospective data. J Am Coll Cardiol. 2009;54:491-498.
67. Strömberg A, Mårtensson J. Gender differences in patients with heart failure. Eur J Cardiovasc Nurs. 2003;2:7-18.
68. Peterson PN, Daugherty SL, Wang Y, Vidaillet HJ, Heidenreich PA, Curtis JP, Masoudi FA; National Cardiovascular Data Registry. Gender differences in procedure-related adverse events in patients receiving implantable cardioverter-defibrillator therapy. Circulation. 2009;119:1078-1084.
69. Fonarow GC, Albert NM, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, McBride ML, Inge PJ, Mehra MR, O'Connor CM, Reynolds D, Walsh MN, Yancy CW. Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). Circulation. 2010;122:585-596.